October 21, 2026 04:46 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Operation completed’: Tiger Shroff shooters allegedly alerted handlers after firing, probe reveals | 'I don't mind saying sorry 1,000 times': Sonu Nigam apologises to Kannadigas over ‘Pahalgam’ remark amid concert ban demand | After Vijay, is Dhanush eyeing politics? TVK calls Thalapathy an inspiration | Trump Says Paris Will Become ‘Muslim City Very Soon’, Blames Macron’s Immigration Policies | Four killed in fresh Manipur violence as protesters take bodies to Chief Minister’s residence | Tiger Shroff firing: Three accused arrested on train in Rajasthan, suspected Bishnoi gang link emerges | 'Internet access a fundamental right for children': SC rejects age-based 'blanket' ban | 'We will fight our own government': RG Kar victim's father threatens fresh protest after Sandip Ghosh gets bail | RG Kar shocker: Sandip Ghosh gets bail as only 7 of 147 witnesses examined, junior doctor blasts CBI | Trump waives Russia-related sanctions
Image credit: UNI

CCI green lights Nirma Ltd's acquisition of Glenmark Life Sciences

| @indiablooms | Dec 20, 2023, at 05:07 am

New Delhi: The Competition Commission of India (CCI) on Tuesday gave its nod to Nirma Limited to acquire the majority shares of Glenmark Life Sciences Limited.

Nirma Limited plans to acquire these shares by purchasing them from Glenmark Life Sciences' promoter and from public shareholders through an open offer, the antitrust watchdog said in a statement.

Nirma Limited has a diverse presence and operations in India and the USA, involved in various products such as soda ash, soaps, detergents, salt, caustic soda, Linear Alkyl Benzene, and other industrial items.

On the other hand, Glenmark Life Sciences is primarily involved in the development, manufacturing, and sale of Active Pharmaceutical Ingredients (APIs) and intermediaries.

It also provides contract development and manufacturing organization (CDMO) services for APIs.

The company's portfolio includes over 130 APIs catering to chronic therapeutic segments like cardiovascular disease, central nervous system disorders, pain management, and anti-diabetics.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.